Bausch + Lomb confirms its organic growth

Due to strong sales in the second quarter, including better-than-expected organic growth at Bausch + Lomb, Bausch Health raised its adjusted Ebitda guidance for the full financial year. The Canadian group - previously called Valeant Pharmaceuticals - now expects it to be in the range of $3,200 to $3,350 million, ...

You need to register to continue reading this article

Already subscribe to Eyewear intelligence? Sign in here

Register to continue reading

By registering today you will have access to:

  • 3 industry news articles per month

For full access and to receive in-depth news, analysis and more, become a member today

For more content and resources become a member? View our membership packages.